CAJ | 학술논문

目的：观察参麦注射液联合培美曲塞(PEM)及奈达铂(NDP)治疗晚期肺腺癌的临床效果。方法将62例晚期肺腺癌患者随机分为治疗组和对照组，治疗组30例，接受PEM及NDP化疗方案治疗，化疗过程中配合参麦注射液静脉滴注；对照组32例，给予PEM及NDP方案化疗。 PEM 500 mg/m2静脉滴入，>10 min，第1天；NDP 80 mg/m2静脉滴入，第1天，21 d为1个化疗周期。2个周期化疗后评价患者的生存质量、临床疗效及不良反应，随访1年。结果治疗组的生存质量评分改善73.3豫，明显高于对照组的46.9豫(P<0.05)。治疗组的有效率为53.3豫，明显高于对照组的28.1豫(P<0.05)。治疗组的1年生存率为63.3豫，明显高于对照组的37.5豫(P<0.05)。治疗组患者出现贫血、白细胞下降、血小板减低的概率低于对照组(P<0.05)。结论参麦注射液联合PEM及NDP方案治疗晚期肺腺癌安全、有效，对改善生存质量、提高近期疗效及保护骨髓功能具有重要作用。
목적：관찰삼맥주사액연합배미곡새(PEM)급내체박(NDP)치료만기폐선암적림상효과。방법장62례만기폐선암환자수궤분위치료조화대조조，치료조30례，접수PEM급NDP화료방안치료，화료과정중배합삼맥주사액정맥적주；대조조32례，급여PEM급NDP방안화료。 PEM 500 mg/m2정맥적입，>10 min，제1천；NDP 80 mg/m2정맥적입，제1천，21 d위1개화료주기。2개주기화료후평개환자적생존질량、림상료효급불량반응，수방1년。결과치료조적생존질량평분개선73.3예，명현고우대조조적46.9예(P<0.05)。치료조적유효솔위53.3예，명현고우대조조적28.1예(P<0.05)。치료조적1년생존솔위63.3예，명현고우대조조적37.5예(P<0.05)。치료조환자출현빈혈、백세포하강、혈소판감저적개솔저우대조조(P<0.05)。결론삼맥주사액연합PEM급NDP방안치료만기폐선암안전、유효，대개선생존질량、제고근기료효급보호골수공능구유중요작용。
Objective To observe the clinical efficacy of Shenmai injection combined with pemetrexed (PEM) and nedaplatin (NDP) in the treatment of advanced lung adenocarcinoma. Methods 62 patients with advanced lung adeno-carcinoma were randomly allocated to the treatment group and the control group.30 patients in the treatment group re-ceived chemotherapy of PEM and NDP, and Shenmai injection was intravenously given during the chemotherapy;32 pa-tients in the control group received chemotherapy of PEM and NDP.PEM of 500 mg/m2 was intravenously given,>10 min,in the first day;NDP of 80 mg/m2 was intravenously given,in the first day.One period of chemotherapy was 21 days. After two periods of chemotherapy,life quality,clinical effects and adverse effect of the patients were assessed.The fol-low-up lasted for 1 year. Results 73.3% of the patients in the treatment group showed an improved life quality,signifi-cantly higher than that of 46.9% in the control group (P<0.05).Effective rate in the treatment group (53.3%) was signif-icantly higher than that of the control group (28.1%) (P<0.05).1-year survival rate in the treatment group (63.3%) was significantly higher than that of the control group (37.5%) (P<0.05).Incidence rate of anemia, decreased white blood cells,and low platelets count were all lower than those in the control group,and the differences between the two groups were statistically significant (P<0.05). Conclusion Shenmai injection combined with PEM and NDP in the treatment of advanced lung adenocarcinoma is safe,effective and plays an important role in improving life quality,enhancing short-term curative effects and protecting the function of bone marrow.